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Abstract
Objective—To evaluate microbiologic effectiveness, i.e. culture negativity of a non-blinded 
eradication protocol (Rx) compared to observation (Obs) in clinically stable cystic fibrosis 
participants with newly positive MRSA cultures.
Design—This non-blinded trial randomized participants ages 4-45 years with first or early (≤2 
positive cultures within 3 years) MRSA positive culture without MRSA-active antibiotics within 4 
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week 1:1 to Rx or Obs. The Rx protocol was: oral trimethoprim-sulfamethoxazole or if sulfa-
allergic, minocycline plus oral rifampin; chlorhexidine mouthwash for two weeks; nasal mupirocin 
and chlorhexidine body wipes for five days, and environmental decontamination for 21 days. The 
primary endpoint was MRSA culture status at day 28.
Results—Between April 1, 2011 to September 2014, forty-five participants (44% female, mean 
age 11.5 years) were randomized (24 Rx, 21 Obs). At Day 28, 82% (n=18/22) of participants in 
the Rx-arm compared to 26% (n=5/19) in Obs-arm were MRSA negative. Adjusted for interim 
monitoring, this difference was 52% (95% CI: 23%, 80%; p<0.001). Limiting analyses to 
participants who were MRSA positive at the screening visit, 67% (8/12) in the Rx and 13% (2/15) 
in the Obs-arm were MRSA negative at Day 28, adjusted difference: 49% (95% CI: 22%,71%, 
p<0.001). Fifty-four percent in the Rx compared to 10% participants in the Obs-arm remained 
MRSA negative through Day 84. Mild gastrointestinal side effects were higher in the Rx-arm.
Conculsions—This MRSA eradication protocol for newly acquired MRSA demonstrated 
microbiologic efficacy with a large treatment effect.
Trial Registration—www.clinicaltrials.gov NCT01349192
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Introduction
Infection with methicillin resistant S. aureus (MRSA) continues to have a significant impact 
in hospital and community acquired infections12. In subjects with cystic fibrosis (CF) the 
prevalence of MRSA positive respiratory cultures increased from 11.9% in 2003 to 25.6% in 
2013 in US CF-centers and contributes to adverse outcomes in CF.34 Cross-sectional, 
epidemiologic studies demonstrated that MRSA was associated with lower lung function in 
CF56 and greater use of medical therapies.7 Longitudinal outcomes of MRSA in CF have 
noted differing results; one study found no difference in lung function decline whereas 
another study showed greater lung function decline in those acquiring persistent MRSA 
infection.8,9 Similarly, CF patients with persistent MRSA infection may have increased 
mortality.10
Treatment approaches highlighted by case series have varied widely from observation to 
long term or intravenous antibiotics with the goal of eradicating MRSA.11-13 Despite the 
evolving concern of this organism in the CF community, to date there are no randomized 
studies demonstrating if treating MRSA at initial detection can eradicate MRSA and prevent 
chronic respiratory infection. Despite MRSA rates being significantly lower than in the U.S., 
many European countries treat any positive respiratory cultures of MRSA and MSSA; 
alternatively, U.S. guidelines do not recommend treatment of incident MRSA or MSSA in 
CF5. The risks of indiscriminate and prolonged treatment of MRSA acquisition include the 
emergence of new/increasingly resistant organisms and treatment related toxicity.
The current study aimed to evaluate the 28 day safety and microbiologic efficacy, i.e. 
microbiologic treatment effect, of a MRSA eradication protocol in CF patients with newly 
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acquired MRSA as compared to observation alone. We hypothesized that patients with CF 
who are clinically stable at time of first detection of MRSA in a respiratory culture are more 
likely to be MRSA culture negative following an intense multi-faceted eradication protocol 
compared to the current U.S. standard of care of not treating MRSA when patients are 
stable.
Materials and Methods
Study Centers
The trial was conducted from April 1, 2011 to September 2014 at 14 CF Foundation 
accredited care centers in the United States. The trial was coordinated by the CF Foundation 
Therapeutics Development Network Coordinating Center (TDNCC; Seattle, WA) and 
registered on clinicaltrials.gov (NCT01349192). Institutional review boards at each 
participating center approved the study and each participant and/or their parent voluntarily 
provided written consent to participate in the trial. Age appropriate assent was obtained as 
indicated.
Study Participants
Eligibility criteria included a confirmed diagnosis of CF, age 4-45 years at time of consent 
and a new onset MRSA positive culture from sputum, or oro-pharyngeal (OP) swab or 
bronchoscopy. New onset was defined as a MRSA positive culture within 6 months that was 
either the first lifetime MRSA positive culture or new emergence of MRSA after at least 1 
year of documented negative cultures (minimum of two cultures/year while off MRSA active 
antibiotics) for MRSA in participants with ≤ 2 MRSA positive cultures in the past 3.5 years. 
After the planned interim review the DMC recommended that the number of study sites be 
increased and that subjects MRSA negative at screening visit be included if the initial 
clinical MRSA isolate was available. This was to enhance enrolment and to reflect clinical 
practice. Participants had to be clinically stable within the 14 days prior to screening. 
Exclusion criteria included having received antibiotics with activity against MRSA or use of 
an investigational drug within 28 days of screening, and FEV1 <30% of predicted based on 
reference equations.1415 Participants with contraindications for study medications i.e. allergy 
or renal or hepatic dysfunction were not eligible. Microbiologic contraindications were 
resistance of the available MRSA isolate to TMP-SMX and minocycline or to rifampin.
Randomization and Blinding
Participants were randomized (1:1) to a MRSA eradication protocol as outlined below or to 
no treatment within strata defined by site, age (4 to 12 years, 13 to 45 years) and presence of 
P. aeruginosa at screening. Randomization assignments were generated via a centralized, 
secure web based randomization system for each enrolled subject. Study personnel and 
participants were not blinded to the treatment regimen.
Treatment Regimen (Rx)
The treatment protocol for those randomized to the MRSA eradication protocol consisted of 
two oral antibiotics for two weeks combined with nasal, skin and oral decontamination as 
well as a three week enhanced household cleaning. Study medications were oral 
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trimethoprim-sulfamethoxazole (TMP-SMX) dosed per CF guidelines at 8 mg/kg 
trimethoprim/40 mg/kg sulfamethoxazole for children <40 kg and 320mg/1600 mg for 
adults given twice daily for 14 days. In participants intolerant to TMP-SMX, minocycline, if 
>8 years, at a dose of 100 mg BID was substituted. All participants randomized to the 
treatment protocol received combination therapy with rifampin (15 mg/kg/day up to 40 kg or 
300 mg BID). Nasal mupirocin and whole body cleansing with chlorhexidine wipes was 
used for 5 days in addition to twice daily gurgling with 0.12% chlorhexidine gluconate oral 
rinse for 14 days. Enhanced household cleaning included weekly washing of linens and 
towels, wiping down high contact surfaces e.g. toys and computers with chlorhexidine and 
extra cleaning of airway clearance devices. Selection of the Rx regimen was based on 
decolonization strategies in non-CF populations and TMP-SMX was selected based on an 
U.S. observational trial in CF which had shown that most MRSA isolates were susceptible to 
TMP-SMX and rifampin, with very low resistance rates to mupirocin.1617
For participants randomized to the observation arm (Obs), treatment with anti-MRSA 
therapy prior to Day 28 was only allowed for a protocol defined exacerbation with choice of 
antibiotics per the participant's treating physician. Use of anti-MRSA antibiotics after Day 
28 was allowed for both arms.
Clinical Evaluations
Medical history, physical examination, specimen sampling for microbiology (OP, nasal, 
groin and axilla swabs on all participants, additional sputum in those expectorating) and 
spirometry were obtained at the screening visit (Day -14). Clinical evaluations, physical 
examination and spirometry were performed at Day 1 (randomization), 15, 28, 84, and 168. 
Follow-up after day 28 was used to assess durability of treatment effect. Pulmonary function 
testing was performed in accordance with American Thoracic Society standards.18 Adverse 
events and concomitant medications were recorded during each visit and by phone calls 
conducted at Day 7. Protocol defined pulmonary exacerbations were defined using a 
combination of spirometry, X-ray and clinical symptoms as in prior studies.19
Primary and Secondary Outcomes
The primary outcome of the study was difference in the proportion of MRSA-negative 
subjects based on OP-swab or sputum at day 28 between the two study arms. Secondary 
endpoints included safety, tolerability of the treatment regimen, protocol adherence, duration 
of microbiologic effect, number of pulmonary exacerbations, use of antibiotics, change in 
spirometry (as measured by FEV1), respiratory symptoms as measured by the CF specific 
patient outcomes: Cystic Fibrosis Questionnaire Revised (CFQ-R) respiratory domain scores 
and Cystic Fibrosis Respiratory Symptom Diary Chronic Respiratory Infection Symptom 
Scale (CFRSD-CRISS), and weight.
Statistical Analysis
The study design specified randomization of 90 participants providing 80% power to detect 
a difference of 30% or greater in the proportion of respiratory cultures negative for MRSA at 
Day 28 (Rx minus Obs). The sample size calculations assumed a dropout rate of 10%, 
ensuring 40 randomized participants to Rx and 40 to Obs-arms.
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Safety outcomes were monitored throughout the trial by a Data Monitoring Committee 
(DMC) appointed by the CF Foundation Safety Monitoring Board. One interim analysis 
with early stopping for futility was scheduled to take place after approximately half of the 
participants had been randomized into the study and had completed the Day 28 visit. 
Because of slow accrual, an early interim review and futility analysis of the primary 
endpoint was initiated when 24 participants had completed the first 28 days of the study. 
Upon review of the interim results, the DMC recommended continuance of the study with a 
second interim analysis for early efficacy. The study team remained blinded to findings 
presented to the DMC. Statistical ramifications of this unplanned efficacy analysis are 
addressed in the Online Supplement.
All of the safety and secondary efficacy analyses were conducted on the Intent-to-Treat 
population (ITT). The primary efficacy analyses were performed on the Intent-to-Treat-
Efficacy (ITT-E) population. The Per-Protocol Efficacy (PPE) population was used in 
sensitivity analyses of the primary endpoint. The detailed definitions of analyses populations 
are provided in Figure 1. T-tests were used to compare continuous variables by study arm. 
The comparisons of proportions were performed using Fisher exact test, with corresponding 
95% confidence interval (CI) derived using the Newcombe-Wilson method. Event rate 
comparisons were performed using Poisson regression. In the analyses of the primary 
endpoint, the difference in the proportion of respiratory cultures negative for MRSA at Day 
28 (Rx minus Obs), the treatment effect, 95% CI's and p-value estimates were adjusted for 
the interim reviews. The use of group sequential stopping rules alters the sampling 
distribution of the usual fixed sample statistics and so adjustments need to be made to 
compute the point estimates, CI's and p-values. The results of final analyses had to be 
adjusted for bias to account for multiple looks at the data during the two interim reviews 
(referred to “adj. for interim monitoring”).
P-values and confidence intervals are two-sided, 0.05 significance level; analyses were 
performed using SAS (version 9.4, SAS Institute Inc., Cary, NC, USA, 2013) and R (version 
3.2.1, The R Foundation for Statistical Computing, Vienna, Austria, 2015).
Results
Although the planned sample size was 90 patients, the DMC recommended that the 
enrollment of new participants be stopped early with ongoing follow-up of enrolled subjects, 
after interim review by the DMC showed a statistically significant microbiological treatment 
effect. At the time the trial was stopped, 73 participants had been screened at 14 
participating centers; 45/73 participants were randomized and followed post-randomization 
(ITT population), 24 in the Rx and 21 in the Obs-arm (Figure 1).
Clinical characteristics of the ITT-participants (n=45) showed a mean age of 11.5 years with 
well-preserved lung function (Table 1). The two arms were comparable at baseline (Table 1) 
and distribution of participants who had a sputum sample in addition to OP swab did not 
differ by study arm (no participant included based on bronchoscopy results). Of the 45 
randomized participants, 41 (22 Rx and 19 Obs) were included in the ITT-E analyses. 
Although the protocol allowed changing from TMP-SMX to minocycline in case of side 
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effects, none changed treatment during the study; however, two subjects in the Rx arm were 
started on minocycline due to previously known intolerances to TMP-SMX. A total of seven 
participants withdrew post randomization (3 [13%] in Rx and 4 [19%] in Obs); 4 withdrew 
before Day 28 visit and were not assessed for the primary microbiologic endpoint (Figure 1).
Table 2 summarizes the primary endpoint, i.e. changes in MRSA culture status from 
screening through Day 28. Those who were not positive at screening had a confirmed 
MRSA isolate at a clinic visit within a median of 46 days (range 14 to 154 days) prior to 
screening. The proportion of participants in the ITT-E population who were MRSA negative 
at Day 28 was 82% (n=18/22) in the Rx compared to 26% (n=5/19) in the Obs-arm. 
Adjusted for the interim reviews, the difference in the proportion being MRSA negative at 
Day 28 (Rx minus Obs) was 52% (95% CI: 23%, 80%; p<0.001). In a sensitivity analysis 
limited to participants who were MRSA positive at the screening visit, 67% in the Rx 
compared to 13% in the Obs-arm were MRSA negative at Day 28, with an adjusted 
difference of 49% (95% CI: 22%,71%, p<0.001). These results prompted the DMC to 
recommend early study closure (see Online Supplement labelled Statistical Monitoring 
Guidelines and Interim Primary Endpoint Analyses).
Table S1 shows results of sensitivity analyses within the first 28 days for the primary 
efficacy endpoint. These sensitivity analyses addressed the use of anti-MRSA antibiotics 
within the first 28 days. For all of the sensitivity analyses, the inference was consistent with 
the primary analysis and in particular, the observed treatment effect was stronger in the PPE 
population.
In the ITT population, fifteen participants (65%) were compliant in their use of both oral 
antibiotics by taking at least 80% doses of rifampin and TMP-SMX, or minocycline (only 
two subjects in this group were treated with minocycline). Overall, the protocol was 
acceptable to patients and families with a relatively low treatment burden (See Online 
Supplement). Adherence with environmental decontamination was very good with 2 
participants (9%) reporting missing ≥5 days of wipes and one participant missing ≥1 time of 
washing the linens. There were three instances of oral antibiotic discontinuation due to 
adverse events “probably related” to study drug: two were temporary discontinuation of 
rifampin due to GI complaints, whereas one participant had to discontinue all antibiotics due 
to urticaria. None of the adverse events were considered serious or required hospitalization. 
Unrelated to adverse events one participant discontinued rifampin early and one participant 
reported taking TMP/SMX only once daily.
Two serious adverse events (SAEs) occurred during the first 28 days on study, one in the Rx-
arm (increased cough) and one in the Obs-arm (cellulitis of the eyelid). Types of adverse 
events were more likely related to gastrointestinal and skin/subcutaneous tissues disorders in 
the treatment arm. No significant laboratory related adverse events were identified (see 
Online Supplement Table S2 and Safety Laboratory Assessment). There were no 
microbiologic adverse events (i.e. no emergent MRSA resistances to antibiotics used or 
appearance of small colony variants).
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Use of anti-MRSA antibiotics is shown by individual participants in Figure 2 from screening 
through Day 168 by study arm together with MRSA culture status. After Day 28, nine (38%) 
participants in the Rx and nine (43%) in the Obs-arm were treated with anti-MRSA 
antibiotics. The usage of non-MRSA active acute oral, inhaled, or IV antibiotic was 
comparable between treatment arms during the first 28 days as well as throughout the study. 
Participant-specific MRSA culture results show that 13 of 24 participants (54%) in the Rx-
arm were MRSA negative at Day 28 and remained negative through Day 84 (Figure 2A) as 
compared to two of 21 (10%) participants in the Obs-arm (Figure 2B). The impact of acute 
antibiotic administration in the Obs-arm on the treatment effect is examined in Online 
Supplement Tables S3.1 and S3.2.
Two participants, one in each arm, were hospitalized during the first 28 days of the study. 
Over the entire course of the study, two (8%) participants in the Rx-arm were hospitalized 
three times and five (24%) were hospitalized in the Obs-arm 11 times (difference = -15%, 
95% CI: -38%, 6%, p=0.22). The rate of hospitalization from screening through Day 168 
was significantly lower in the Rx vs. the Obs-arm (RR = 0.22, 95% CI: 0.05, 0.72, p=0.01).
The proportion of participants experiencing at least one pulmonary exacerbation between 
screening and Day 28 (calculated as the proportion of patients experiencing an event per 28 
days of follow-up) was 13% in the Rx-arm as compared to 33% in the Obs-arm (95% CI: 
-44%, 4%, p=0.15). Similarly, the rate of exacerbation from screening through Day 28 was 
lower in the Rx-arm vs. Obs-arm, (RR = 0.36, 95% CI: 0.08, 1.29, p=0.12), although not 
statistically significant.
At screening 14 of 45 participants had nasal MRSA colonization. The proportion colonized 
was similar in the two treatment arms: six of 24 (25%) in the Rx and eight of 21 (38%) in 
the Obs-arm (p=0.52). No treatment related differences emerged. Only one patient was 
MRSA colonized at the skin (Supplement Tables S4.1, S4.2). Participants with persistent or 
re-emergent MRSA infection kept the same SCCmec type. There were no differences in 
proportion colonized with P. aeruginosa at screening, with four of 24 (17%) in Rx and 4 of 
21 (19%) in the Obs-arm (p>0.999). No differences emerged during the course of the trial.
At Day 28, the mean relative change in FEV1 (L) from screening was 2.5% in the Rx-arm 
(n=19) and -2.4% in the Obs-arm (n=16) (difference = 4.9%, 95% CI: -0.6%,10.4%, 
p=0·08); the mean absolute change in FEV1 (% predicted) was 0.7% in the Rx-arm and 
-4.1% in the Obs-arm with a difference of 4.8%, (95% CI: -0.9%,10.5%, p=0.10). At Day 
168, the differences (Rx-Obs) in mean relative change in FEV1 (L) was 3·1% (95% CI: 
-2.5%, 8.6%, p=0.27) and the mean absolute change in FEV1 (% predicted), 4·7% (95% CI: 
-0.4%, 9.8%, p=0.07) (See Figure 3). Figure S1.1 and S1.2 show the changes in FEV1 
(Liters) and FEV1 (% predicted)).
There were no significant differences between study arms with respect to changes in weight 
or patient reported outcomes (Online Supplement Figures S2.1, S2.2, S2.3, S3.1, and S3.2).
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Discussion
Prevalence of MRSA in CF is ∼26% in the U.S. and chronic infection has been associated 
with higher rates of lung function decline and mortality.910 The current randomized 
controlled trial evaluated a comprehensive protocol with two oral antibiotics for two weeks 
combined with nasal, skin, and oral decontamination as well as a three week environmental 
decontamination in clinically stable CF patients. This treatment led to a marked reduction in 
culture positivity (OP swab or sputum) at 28 days compared to the observational arm. The 
treatment effect was large enough to recommend early study termination by the DMC due to 
evidence of microbiologic efficacy, i.e. the high rate or MRSA negative cultures in the 
treatment compared to the observation arm. Positive trends were also seen for secondary 
outcomes with reduction in the rate of pulmonary exacerbation and a trend towards 
improved lung function despite the study population having preserved lung function at 
baseline. As expected for these antibiotics, the rate of GI side effects was higher in the Rx 
arm, however the only permanent discontinuation of antibiotics was for urticaria. Thus, the 
treatment regimen appeared overall safe and, despite some drug related side effects, well 
tolerated. Despite most participants reporting that the regimen was acceptable, compliance 
with all aspects of this regimen was not ideal, which may be related to the multi-faceted 
approach.
The possibility of treating MRSA successfully and achieving eradication even in settings of 
chronic infection has been reported.11-1320-22 None of these studies included a control arm 
and all had smaller sample sizes than the current study. Despite these limitations, they 
demonstrated the potential benefit of eradication. Of note, these reports included countries 
and CF centers with much lower MRSA prevalence than the U.S., which would be 
especially relevant in examining rates of MRSA recurrence. A systemic review for the early 
treatment of MRSA in CF concluded that there were no randomized trials available to assess 
early eradication.23
The protocol specified antibiotics were based on drug availability, cost, synergy and 
antibiotic susceptibility in CF MRSA isolates in the U.S.16,24,17 Although fusidic acid 
showed low rates of resistance for U.S. CF MRSA isolates17 and that MRSA eradiation 
protocols outside the U.S. reported combination therapy with fusidic acid and rifampin, this 
drug is not approved in the U.S. We included nasal or throat decontamination procedures 
based on the use of mupirocin in non-CF eradication/decontamination25 and the high rate of 
positive throat cultures in CF.26 Skin decontamination was included based on possible high 
skin colonization with SCCmec IV isolates and approaches in non-CF decolonization.27 
Interestingly, despite high rates of SCCmec IV MRSA, skin positivity was rare and the 
topical skin treatment may not be essential in CF. Further trials comparing our intense 
protocol to less elaborate treatment approaches are required to demonstrate whether skin 
decontamination is required.
This study was primarily designed as a controlled trial of MRSA treatment with a short 
controlled microbiology outcome. Thus, longer term clinical outcomes after day 28 in our 
trial are harder to interpret given the very high rate of oral, intravenous and inhaled 
antibiotics (many with anti-MRSA activity) in both study arms, even in subjects not 
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culturing MRSA (Fig. 2). The participant and treatment heterogeneity after the intervention 
period limited interpretation of long term clinical outcomes and we are not able to 
definitively comment regarding long term lower airway eradication. At day 84, a higher 
proportion of participants in the Rx-arm than in the Obs-arm were still MRSA negative. It is 
difficult to evaluate if recurrence of MRSA is due to persistence not detected by culture or 
due to reinfection and, although repeat isolates were of the same SCCmec type, this method 
has insufficient sensitivity to address high degree genetic relatedness. Further studies will 
need to address these questions. Prior literature has demonstrated heavy antibiotics use in 
U.S. MRSA-positive CF populations.28,29,30
Two aspects of the study warrant special attention and should be considered in regards to 
generalisability of results. First, because of poor enrollment rates, the number of study sites 
was expanded and participants were allowed to be enrolled if they had MRSA isolated from 
the respiratory tract (sputum or OP culture) at the most recent clinical care visit if this 
MRSA isolate was available for susceptibility testing. This amendment mirrored common 
clinical practice and was similar to the approach taken in the Early Pseudomonas Infection 
Control trial.19 Importantly, when the primary endpoint was analyzed based only on 
participants who were culture positive for MRSA at screening (27/41 in ITT-E population), 
the results were similar.
Second, the study was stopped based on an unplanned efficacy interim analysis. 
Interestingly, early stopping for microbiologic efficacy was also initiated in the early inhaled 
tobramycin eradication trial.31 At the first, planned review, the DMC recommended an 
unplanned interim efficacy analysis. In response to this unplanned review, additional 
statistical analyses evaluated the sensitivity of the results to variations in stopping rules (see 
Online Supplement Table S1).32-36 Because the stopping rule for efficacy was not specified 
in advance, this sensitivity analysis assessed how sensitive the inference (related to the 
difference in the proportion MRSA negative between study arms) was to a myriad of 
stopping rules that the DMC could have considered. These estimates of treatment differences 
adjusted for the corresponding group sequential stopping rule are shown in detail in Table 
S1.
This trial was not blinded to either staff or participants because several of the interventions 
e.g. rifampin could not be blinded. However, the primary endpoint was an objective measure 
i.e. culture positivity. This design may have led to higher use of antibiotics in the Obs arm 
after day 28.
There are a number of important limitations to interpreting the results of this clinical trial. 
First, only participants ages 4-45 years with early MRSA infection were included. Thus, one 
cannot infer that this protocol would have a similar treatment effect in patient groups not 
fulfilling these inclusion criteria. Consistent with the highest incidence of MRSA occurring 
in mid-childhood in the U,S, CF population, the majority of participants were children with 
FEV1 >75% predicted (Table 1) and the majority could not expectorate sputum. Further, 
patients presenting in the setting of an acute exacerbation who were culture positive for 
MRSA or who had received antibiotics effective against MRSA in the prior 28 days were 
excluded. These participant characteristics and other exclusion criteria limit the extension of 
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these results to the broader CF population infected with MRSA. Last, the study was not 
designed to assess the long term impact of MRSA eradication or effect of repeated treatment 
MRSA eradication courses. Data gathered in the observational extension portion of the study 
noted that both Rx and Obs-arms received multiple courses of antibiotics with potential 
MRSA activity.
Our study did demonstrate that spontaneous clearance of MRSA at day 28 does occur at a 
rate of approximately 13% in those that were culture positive at screening and 26% in the 
entire observation arm. Data from the U.S. CF Registry database collected from 1996-2006 
indicates that among patients ages ≥6 years up to 50% of subjects have only one time 
positive MRSA cultures or intermittent MRSA infection, however treatment history is 
missing on these subjects.10 Such data however do highlight the value to repeat cultures 
prior to eradication attempts if one was to employ such a protocol.
Conclusion
This trial is the first randomized clinical trial to study the microbiologic impact of an 
eradication protocol. While there was a significant difference in microbiological success and 
evidence towards fewer exacerbations in the Rx-arm in this short trial, more questions 
remain prior to recommending universal early anti-MRSA therapy. These include 
optimization of the treatment regimen i.e. are all measures necessary and assessing 
individuals who either have mild exacerbations or are outside the currently selected age 
range. The high rate of antibiotic use after the primary endpoint begs the question if a repeat 
course is indicated in those who remain culture positive at the end of the treatment. These 
questions will need further clinical trials and close observation of clinical practice in all 
countries. However, we did demonstrate that currently available antibiotics with a well-
established safety profile are effective in early MRSA infection.
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Refer to Web version on PubMed Central for supplementary material.
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What is the key question?
Is aggressive treatment of incident MRSA positive respiratory culture in cystic fibrosis 
(CF) effective at reducing MRSA culture positivity and is it clinically safe?
What is the bottom line?
This multi-faceted oral, topical and environmental treatment protocol demonstrated a 
strong microbiologic treatment effect in children and adults with few treatment related 
side effects, which were mostly gastrointestinal and skin-related.
Why read on?
To learn about the duration of MRSA negative cultures and secondary outcomes, which 
showed favorable trends despite a small sample size.
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Figure 1. CONSORT diagram of participant disposition
Flow diagram of participants through each stage of the randomized trial.
Footnote: Nine participants did not meet the inclusion criteria of being clinically stable. One 
of these participants was subsequently re-screened but failed the inclusion criteria of MRSA 
positive culture at screening or within 6 months prior to screening.
Eleven participants failed the inclusion criteria of MRSA positive culture at screening or 
within 6 months prior to screening.
One participant did not meet the inclusion criteria by withdrawing their consent.
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One participant did not meet the inclusion criteria of having a documented CF diagnosis.
Two participants met the exclusion criteria of receiving anti-MRSA antibiotics within 28 
days prior to screening.
One participant met the exclusion criteria of abnormal renal function at screening.
One participant met the exclusion criteria that warranted a screen failure due to investigator's 
opinion.
[2] Two participants randomized to the observational control arm withdrew with reason 
“Subject decision”.
[3] The intent-to-treat (ITT) population is defined as participants who are randomized to a 
study arm and followed post randomization. The ITT population is used for all safety and 
secondary efficacy analyses.
[4] One site, which enrolled a total of four participants (two in the treatment arm, two in the 
observational control arm), experienced numerous study conduct issues and protocol 
violations resulting in missing primary endpoint and other endpoint data. One of these four 
participants had withdrawn immediately following randomization to the observational 
control arm. The remaining three participants' data is summarized as available post-
randomization.
[5] The intent-to-treat efficacy (ITT-E) population consists of all the participants in the ITT 
population who were assessed for the primary microbiologic efficacy endpoint at baseline 
and Day 28. The ITT-E population is used for the primary efficacy analyses.
[6] The per-protocol efficacy population (PPE) is comprised of all participants in the ITT-E 
population excluding the participants with major protocol violation or those non-compliant 
with oral antibiotic use during the first 28 days of the study. The PP population is used in 
sensitivity analyses of primary efficacy endpoint.
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Figure 2. (A Rx and B Obs-arm) Participant-specific MRSA culture results through Day 168 by 
treatment arm
Individual participant MRSA culture status across time is shown. History of MRSA positive 
isolate is also shown. Participants with who are P. aeruginosa positive (Pa +) are indicated by 
□. Acute events treated with anti-MRSA active antibiotics are marked with an ‘X’. The 
locations of the ‘X’s indicate the timing of the antibiotic course in relationship to the study 
visits but do not represent an actual day as measured from screening. Participants enrolled 
prior to protocol amendment are marked with an asterisk (see Discussion).
Muhlebach et al. Page 18
Thorax. Author manuscript; available in PMC 2018 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 3. Relative change from screening in FEV1 (Liters) over time by study arm (ITT 
Population)
Relative change in FEV1 (Liters) from baseline to each post-baseline visit for both study 
arms in ITT population is shown. 95% confidence intervals (using t-distribution 
approximation) are included at each time point. The number of participants at each time 
point is included in a legend below the figure. Per protocol, participants younger than 6 
years of age from both the treatment arm (n=3) and observational control arm (n=4) were 
not assessed for pulmonary function.
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Table 1
Demographics and Baseline Characteristics by Study Arm
This table summarizes demographic and baseline characteristics by study arm in the ITT population. All 
measures were recorded at Screening.
No. (%)
Treatment (N = 24) Observational Control (N = 21) Total (N = 45)
Sex – Female 10 (42) 10 (48) 20 (44)
Race
Caucasian 19 (79) 17 (81) 36 (80)
Hispanic 3 (13) 2 (10) 5 (11)
African-American 1 (4) 1 (5) 2 (4)
Other 1 (4) 1 (5) 2 (4)
Genotype
F508 del Homozygous 6 (25) 12 (57) 18 (40)
F508 del Heterozygous 14 (58) 7 (33) 21 (47)
Other [1] 4 (17) 2 (10) 6 (13)
Age Group
4 - 12 years 13 (54) 15 (71) 28 (62)
>12 - 18 years 6 (25) 5 (24) 11 (24)
>18 years 5 (21) 1 (5) 6 (13)
P. aeruginosa Positive 4 (17) 4 (19) 8 (18)
FEV1 % Predicted Group [2]
30% - 50% predicted 1 (5) 0 (0) 1 (3)
>50% - 75% predicted 1 (5) 0 (0) 1 (3)
>75% - 100% predicted 7 (35) 5 (29) 12 (32)
>100% predicted 11 (55) 12 (71) 23 (62)
Mean (SD)
Age (years) 12.3 (6.6) 10.5 (5.5) 11.5 (6.1)
FEV1 % Predicted [2] 98.5 (21.6) 101.2 (11.8) 99.8 (17.6)
Weight (kg) 40.5 (17.0) 38.2 (19.8) 39.4 (18.2)
Weight (%)[3] 50.5 (27.4) 53.7 (23.9) 52.0 (25.5)
Body Mass Index (%)[3] 60.8 (25.4) 64.6 (20.5) 62.7 (23.0)
[1]Other refers to participants with either two known, non-Delta F508 CF mutations, or one known, non-F508 del CF mutation and one unidentified 
allele which has not been classified as a CF mutation.
[2]
For participants 6 years or older, FEV1 % predicted is calculated based on the Wang (males < 18 years, females < 16 years) or Hankinson 
(males ≥ 18 years, females ≥ 16 years) reference equations. Percentages are based on number of participants with FEV1 measurements available 
(20 in the treatment arm and 17 in the observational control arm).
[3]
The percentiles are derived using CDC standards for participants ≤ 20 years old.
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Table 2
Microbiologic Effect at Day 28
This table summarizes analysis of primary endpoint, i.e. proportion of participants in the ITT-E population 
with a MRSA-negative culture at Day 28, adjusted for interim review. Also summarized is the proportion of 
MRSA-negative cultures at Day 28 among participants with a MRSA-positive culture at screening. For 
participants that have both an OP and expectorated sputum sample available at a given visit, a positive 
respiratory culture result is based on MRSA being present in either the OP or expectorated sputum sample; a 
negative result is based on MRSA being absent from both the OP and expectorated sputum samples.
Treatment (N=24) Observational Control (N=21) Difference (95% CI) p-value
Screening
Number screened 24 21
MRSA Positive at screen, n (%) 14 (58%) 17 (81%)
-23% (-45%, 4%)[1] 0.12[2]
Day 28
Number completed 22 19
MRSA Negative at Day 28, n (%) 18 (82%) 5 (26%) 52% (23%, 80%)[3] <0.001 [3]
Change from Screening to Day 28
Number Cultures MRSA Positive at Screening 
[4]
12 15
Changed to MRSA Negative from Screening to 
Day 28, n (%) [5]
8 (67%) 2 (13%) 49% (22%, 71%)[3] <0.001 [3]
[1]95% confidence interval calculated using the Newcombe -Wilson method without continuity correction.
[2]
The p-value is obtained from the Fisher's exact test.
[3]Adjusted for the interim reviews.
[4]Number of participants with both a MRSA positive respiratory culture result available at Screening, and a non-missing MRSA culture result at 
Day 28.
[5]
Percent value is based on the number of participants with a MRSA positive respiratory culture result available at Screening.
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